FDA and Novo Nordisk Issue Warning About Counterfeit Ozempic

The U.S. Food and Drug Administration (FDA) along with pharmaceutical leader Novo Nordisk has issued a warning to consumers regarding the presence of counterfeit Ozempic (semaglutide) in the drug supply chain across the United States. Counterfeit versions of Ozempic, a medication commonly prescribed for type 2 diabetes and weight management, have been identified and are concerning for patient safety.

Several hundred units of fake Ozempic injection 1 mg have been seized. These illegitimate products are identified by a genuine lot number, PAR0362, but contain false serial numbers starting with the digits 51746517. Any product bearing this specific lot number combined with the incorrect serial number should be considered counterfeit.

Currently, the FDA and Novo Nordisk are testing the seized drugs to determine their safety, quality, and potential risks. At this stage, there is no conclusive information about the safety profile of these counterfeit products. Moreover, the FDA has received six adverse event reports associated with the lot of Ozempic in question. However, these reports, submitted by Novo Nordisk, do not appear to be linked to the counterfeit drugs.

Patients and pharmacies are strongly advised to inspect the packaging of their Ozempic. If the lot number and serial number match the counterfeit criteria, they should not use the medication and report it immediately to Novo Nordisk or the FDA. It is crucial to stay vigilant as consuming counterfeit medications can pose serious health risks.

Consumers who experience any adverse effects after using Ozempic should report these incidents via the FDA’s MedWatch Safety Information and Adverse Event Reporting Program or contact Novo Nordisk directly at 1-800-727-6500.

For further information, visit the FDA’s official warning at FDA Drug Safety. Ensuring medication safety is vital, especially with the increasing presence of counterfeit drugs in the market.